• TOP
  • >Corporate Profile

Corporate Profile

Corporate Profile

Corporate Name MiRTeL Co., Ltd.
Founded September 2012
Capital 95,000,000 JPY
Executive officers
Representative Director CEO & President

Eiji Tahara
Executive Vice President COO

Toshiya Kato
Board Director
Naoki Tomokami
External Board Director

Atsushi Usami
External Board Director

Mayu Yoshikawa
External Board Director

Nishino Kazumi
External Board Director

Kenichi Kumagai
Audit & Supervisory Board Member

Hitoshi Iyomoto
Audit & Supervisory Board Member

Toshiharu Ko
Audit & Supervisory Board Member

Toru Takiguchi
Business year from January 1 to December 31

Hiroshima Headquarters

Tokyo Office

Description of business
  1. Research and development of health check systems
  2. Undertaking of medical clinical laboratory tests and other examinations related to public health
  3. Sales and leasing of apparatus, devices and equipment for clinical laboratory tests, and of medical supplies, and installation, maintenance and repair of same
  4. Provision of clinical laboratory tests and clinical diagnosis services in collaboration with doctors
  5. Planning, development, management and operation of information systems related to medical and clinical laboratory tests, and sales and consulting services
  6. Analysis of risk of disease onset, summarization of test results and contract services regarding associated examinations
  7. Contract services regarding testing related to drugs and health foods, etc. and research, development, manufacturing, sales and import/export of such products
  8. Collection and distribution of samples, reagents, data and test results, etc. related to clinical laboratory tests
  9. Manufacture and sale of kits for DNA measurement (e.g., telomere length)
  10. Manufacture and sale of accessory products related to microRNA
  11. Introduction of pharmacists, nurses and clinical laboratory technicians to health care facilities, and corresponding mediation
  12. Licensing of services related to drugs, quasi-drugs, clinical laboratory reagents, and chemical agents, etc.
  13. Management of clinical testing laboratories
  14. All businesses associated with or related to any of the items listed above
History
September 2012
Foundation of MiRTeL Co., Ltd.
August 2013
Foundation of testing laboratory (address: 1-2-10 Deshio, Minami-ku, Hiroshima)
September 2013
Authorization as Hygiene and Public Health Center
September 2013
Start of contracting of Telomere test
December 2013
Start of contracting of MiR test® (pancreatic cancer, breast cancer, Alzheimer type dementia)
March 2015
Start of MiR test® cancer screening test (MiR test® Premium)
September 2015
Receipt of funds from NTT DOCOMO Ventures, Inc., start of joint investigation with NTT DOCOMO, INC., receipt of funds from Medical Net Communications, Inc. and business partnership
July 2016
Third-party share issue totaling 190 million JPY allocated to The University of Tokyo Edge Capital (UTEC) Co., Ltd., Hiroshima Venture Capital Co., Ltd., WILL GROUP, INC., NTT DOCOMO Ventures, Inc., and Medical Net Communications, Inc.
October 2016
Establishment of Tokyo Office (New Marunouchi Building 10F, EGG JAPAN)
November 2016
First prize (Prize of Chairman of the Organization for Small & Medium Enterprises and Regional Innovation) in the entrepreneur section of the ""11th awarding of the prize for creating new business in Japan"" sponsored by the Japan New Business Conference Associations.
October 2017
Special prize at Chugoku District tournament of the Ernst & Young ShinNihon LLC Entrepreneur of the Year 2017 Japan
June 2018
Third-party share issue totaling 580 million JPY allocated to Beyond Next Ventures Inc., The University of Tokyo Edge Capital (UTEC) Co., Ltd., Hiroshima Venture Capital Co., Ltd., KYOCERA Corporation and Medical Net, Inc.
June 2018
Start of contracting of MiR test® Platinum and telomere fatigue level test
April 2020
This Third-party share issue totaling 460 million JPY, is allocated to Furusato cooperation support fund investment limited partnership run by Hiroshima Innovation Network Inc., TEIJIN LIMITED, and High-Value C 1st investment limited partnership run by Hiroshima Venture Capital Co., Ltd.
May 2020
Acquisition of Privacy Mark.
E-mail:info@mirtel.co.jp
URL:https://www.mirtel.co.jp/english/
Headquarters/Hiroshima Laboratory
1-2-10 Deshio Minami-ku, Hiroshima 734-0001, Japan
TEL:+81-82-546-9797
FAX:+81-82-546-9790
  • From Hiroshima Station south exit bus terminal Platform B-7, take bus #(302,321,322)
    bound for Daigakubyoin (University Hospital) and alight at the "Daigakubyoin" bus stop (terminal)
Hiroshima Office
Room No. 302, Paruru Ai Bld., 2-12-27 Danbara-Minami, Minami-ku, Hiroshima, 732-0814, Japan
TEL:+81-82-546-9797
FAX:+81-82-236-1280
  • From Hiroshima Station south exit bus terminal Platform B-7, take bus #(302,321,322)
    bound for Daigakubyoin (University Hospital) and alight at the "Danbara Minami" bus stop
Tokyo Office
TERRACE SITE Yotsuya 5F,
12-7 Yotsuya Saneicho, Shinjuku-ku, Tokyo 160-0008, Japan
TEL:+81-3-4530-6011
FAX:+81-50-6865-7663
  • 6 minute walk from Tokyo Metro Marunouchi line Yotsuya-sanchome station
  • 8 minute walk from JR Chuo line Yotsuya station
  • 8 minute walk from Toei Shinjuku line Akebonobashi station